Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1241.80
-28.00 (-2.21%)
< Home < Back

Dr. Reddy's Laboratories’ arm announces commercial availability of ZEMBRACE SymTouch

Date: 19-04-2016

Dr. Reddys Laboratories’ subsidiary -- Promius Pharma has announced that ZEMBRACE SymTouch (sumatriptan injection) 3 mg, approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the US.

ZEMBRACE SymTouch is a prefilled, low-dose, ready to use, 2-step autoinjector containing 3mg of sumatriptan a selective 5-HT1B/ID receptor agonist. Because ZEMBRACE SymTouch is a subcutaneous injection, it may lead to rapid relief in migraine.

Dr. Reddy's Laboratories, is a multinational pharmaceutical company based in Hyderabad, Telangana in India. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas.